Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9828
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAng, Jianen
dc.contributor.authorLijovic, Marijanaen
dc.contributor.authorAshman, Leonie Ken
dc.contributor.authorKan, Kathleenen
dc.contributor.authorFrauman, Albert Gen
dc.date.accessioned2015-05-15T23:05:02Z
dc.date.available2015-05-15T23:05:02Z
dc.date.issued2004-11-01en
dc.identifier.citationCancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association For Cancer Research, Cosponsored By the American Society of Preventive Oncology ; 13(11 Pt 1): 1717-21en
dc.identifier.govdoc15533898en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9828en
dc.description.abstractCD151 is the first member of the tetraspanin family to be associated as a promoter of human tumor metastasis. However, its biological function and expression phenotype among different tumors has not been well investigated.Tissue specimens from 76 primary prostate cancers and 30 benign prostate hyperplasia (BPH) controls were obtained from the Department of Anatomical Pathology at the Austin and Repatriation Medical Centre (now Austin Health) from 1984 to 1993. We used quantitative immunohistochemical analysis to measure CD151 protein expression. Analyses of differences among BPH and prostate cancer groups were done with one-way ANOVA and Newman-Keuls test. The Kaplan-Meier method and the log-rank test were used to estimate the overall survival.CD151 expression was found to be significantly higher in prostate cancer specimens compared with BPH specimens (P < 0.001). Poorly differentiated cancers expressed the strongest staining, whereas well-differentiated cancers expressed the weakest staining for CD151 (P < 0.001). The overall survival rate for cases in which CD151 expression was reduced was significantly higher than for cases in which CD151 expression was increased (P = 0.039) especially in well and moderately differentiated cancers (P = 0.014). This effect was independent of the patients' age or preoperative prostate-specific antigen values and superior in the predictive ability of the Gleason score.CD151 has an increasing expression pattern in prostate cancer progression, and higher levels of CD151 are associated with poorer prognosis. CD151 had better predicting value for the clinical outcome of prostate cancer patients than does the traditional histologic grading method (Gleason grading).en
dc.language.isoenen
dc.subject.otherAntigens, CD.metabolismen
dc.subject.otherAntigens, CD151en
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherNeoplasm Stagingen
dc.subject.otherPrognosisen
dc.subject.otherProstatic Hyperplasia.metabolism.pathologyen
dc.subject.otherProstatic Neoplasms.metabolism.pathologyen
dc.subject.otherSurvival Rateen
dc.subject.otherTumor Markers, Biologicalen
dc.titleCD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyen
dc.identifier.affiliationClinical Pharmacology and Therapeutics Unit, Austin Health, Department of Medicine, University of Melbourne, Level 5, Lance Townsend Building, Studley Road, Heidelberg, Victoria, Australiaen
dc.description.pages1717-21en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15533898en
dc.type.austinJournal Articleen
local.name.researcherFrauman, Albert G
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Jun 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.